1. In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect
- Author
-
Houcemeddine Othman, Imen Ben Mustapha, Maher Kharrat, Kais Ghedira, Henda Triki, Rabeb Touati, Sondes Haddad-Boubaker, Kaouther Ayouni, Marwa Lakhal, Laboratoire de Virologie Clinique, Référence Régional OMS pour la Poliomyélite et la Rougeole - Laboratory of Clinical Virology, WHO Regional Reference Laboratory on Poliomyelitis and Measles, Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Université de Tunis El Manar (UTM), Virus, Vecteurs et Hôtes [Tunis], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), University of the Witwatersrand [Johannesburg] (WITS), Laboratoire de Transmission, Contrôle et Immunobiologie des Infections - Laboratory of Transmission, Control and Immunobiology of Infection (LR11IPT02), Laboratoire de Bioinformatique, biomathématiques, biostatistiques (BIMS) (LR11IPT09), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Tunis El Manar (UTM), This study was funded by the Tunisian Ministry of Higher Education and Scientific Research (Research laboratory: Virus, Vectors and Hosts, LR20IPT10). It was also partially supported by the European project PHINDaccess: Strengthening Omics data analysis capacities in pathogen-host interaction (Grant Agreement ID: 811034)., and European Project: 811034,H2020-EU.4.b.,PHINDaccess(2018)
- Subjects
Protein Conformation ,Cross Protection ,[SDV]Life Sciences [q-bio] ,OPV ,Biochemistry ,0302 clinical medicine ,MESH: Protein Conformation ,Structural Biology ,MESH: COVID-19 ,BCG ,030212 general & internal medicine ,Antigens, Viral ,lcsh:QH301-705.5 ,0303 health sciences ,Tetanus ,Applied Mathematics ,Viral Vaccine ,Immunogenicity ,Hepatitis B ,MMR ,Computer Science Applications ,3. Good health ,MESH: BCG Vaccine ,MESH: COVID-19 Vaccines ,BCG Vaccine ,lcsh:R858-859.7 ,MESH: Antigens, Viral ,Research Article ,Antigenicity ,COVID-19 Vaccines ,In silico ,Putative protection ,Biology ,lcsh:Computer applications to medicine. Medical informatics ,Measles ,03 medical and health sciences ,Viral Proteins ,Antigen ,MESH: Computer Simulation ,MESH: Viral Vaccines ,medicine ,Humans ,Computer Simulation ,MESH: SARS-CoV-2 ,Molecular Biology ,030304 developmental biology ,MESH: Humans ,SARS-CoV-2 ,COVID-19 ,Viral Vaccines ,medicine.disease ,Virology ,MESH: Viral Proteins ,MESH: Cross Protection ,lcsh:Biology (General) ,Vaccine - Abstract
Background Coronavirus Disease 2019 (COVID-19) is a viral pandemic disease that may induce severe pneumonia in humans. In this paper, we investigated the putative implication of 12 vaccines, including BCG, OPV and MMR in the protection against COVID-19. Sequences of the main antigenic proteins in the investigated vaccines and SARS-CoV-2 proteins were compared to identify similar patterns. The immunogenic effect of identified segments was, then, assessed using a combination of structural and antigenicity prediction tools. Results A total of 14 highly similar segments were identified in the investigated vaccines. Structural and antigenicity prediction analysis showed that, among the identified patterns, three segments in Hepatitis B, Tetanus, and Measles proteins presented antigenic properties that can induce putative protective effect against COVID-19. Conclusions Our results suggest a possible protective effect of HBV, Tetanus and Measles vaccines against COVID-19, which may explain the variation of the disease severity among regions.
- Published
- 2021